Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04134936
Recruitment Status : Active, not recruiting
First Posted : October 22, 2019
Last Update Posted : October 14, 2020
Sponsor:
Information provided by (Responsible Party):
MorphoSys AG

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : August 2021
Estimated Study Completion Date : January 2023